A 42-year-old woman presents with a 2-day history of dysuria, urinary frequency, and visible haematuria. She reports similar episodes twice in the past year. She has no fever or loin pain. Urine dipstick shows blood 3+, leucocytes 2+, nitrites positive, protein 1+. Midstream urine culture grows >10^5 colony-forming units/mL of Escherichia coli sensitive to trimethoprim and nitrofurantoin. What is the most appropriate next step in her management after completing antibiotic treatment?
Q12
A 75-year-old man with benign prostatic hyperplasia presents to the emergency department with a 12-hour history of complete inability to pass urine and severe suprapubic pain. Clinical examination reveals a palpable bladder extending to the umbilicus. A urinary catheter is successfully inserted, draining 1200 mL of urine immediately. Over the next 4 hours, he produces a further 2500 mL of urine. Blood tests show: sodium 145 mmol/L, potassium 3.8 mmol/L, creatinine 156 μmol/L (baseline 95 μmol/L). What is the most appropriate immediate management?
Q13
A 58-year-old woman with rheumatoid arthritis treated with methotrexate and NSAIDs presents with a 3-day history of vomiting and diarrhoea. Her baseline creatinine is 78 μmol/L. Current blood tests show: creatinine 245 μmol/L, urea 18.2 mmol/L, sodium 132 mmol/L, potassium 5.2 mmol/L. Urinalysis shows no protein or blood. Renal ultrasound shows normal-sized kidneys with no hydronephrosis. What is the most likely underlying mechanism of her acute kidney injury?
Q14
A 62-year-old man with chronic kidney disease stage 3b (eGFR 40 mL/min/1.73m²) is being evaluated for worsening renal function. His medication history includes ramipril, atorvastatin, and amlodipine. Blood tests show: haemoglobin 102 g/L, ferritin 450 μg/L, transferrin saturation 18%, serum vitamin B12 320 ng/L, folate 8 μg/L. What is the most appropriate interpretation of these haematological findings?
Q15
A 45-year-old woman presents to the emergency department with severe muscle weakness and palpitations. She has a history of hypertension treated with lisinopril and bendroflumethiazide. ECG shows tall tented T waves and a prolonged PR interval. Blood tests reveal: sodium 138 mmol/L, potassium 7.8 mmol/L, creatinine 95 μmol/L, glucose 5.2 mmol/L. Which medication should be given first to protect against the cardiac effects of hyperkalaemia?
Q16
A 47-year-old woman presents with severe nausea and decreased urine output 24 hours after undergoing contrast-enhanced CT pulmonary angiogram for suspected pulmonary embolism. Her background includes type 2 diabetes (HbA1c 76 mmol/mol) and hypertension treated with lisinopril and metformin. Pre-CT creatinine was 142 μmol/L. Current blood tests show: creatinine 287 μmol/L, urea 19.4 mmol/L, potassium 5.2 mmol/L. Urinalysis shows muddy brown casts. Which feature of her presentation would most strongly indicate a need for urgent haemodialysis?
Q17
A 61-year-old man with CKD stage 5 (eGFR 12 mL/min/1.73m²) presents for pre-dialysis assessment. His blood tests show: haemoglobin 92 g/L, ferritin 380 ng/mL, transferrin saturation 28%, PTH 68 pmol/L (reference 1.6-6.9 pmol/L), corrected calcium 2.28 mmol/L, phosphate 1.89 mmol/L, 25-OH vitamin D 32 nmol/L, bicarbonate 18 mmol/L. Which intervention would address the greatest number of complications in this patient?
Q18
A 35-year-old man presents to the emergency department with a 4-hour history of severe right loin pain, haematuria, and vomiting. CT KUB confirms a 4mm stone in the right ureter with mild hydronephrosis. He is treated with IM diclofenac and IV fluids. Six hours later, he develops fever of 38.7°C with rigors. Blood tests show: WBC 17.8 × 10⁹/L, CRP 142 mg/L, creatinine 156 μmol/L (baseline 88 μmol/L). Blood pressure is 98/62 mmHg, pulse 118 bpm. What is the most appropriate immediate management?
Q19
A 41-year-old man with autosomal dominant polycystic kidney disease and CKD stage 3a (eGFR 52 mL/min/1.73m²) is commenced on tolvaptan following nephrologist review. He is counselled about potential adverse effects. Which of the following monitoring protocols is most critical for this medication?
Q20
A 67-year-old woman is being investigated for recurrent urinary tract infections. She has had 5 documented UTIs in the past 8 months, each confirmed with positive urine culture and responding to antibiotics. She is postmenopausal and has type 2 diabetes (HbA1c 58 mmol/mol). Renal ultrasound shows normal kidneys with no evidence of obstruction or stones. Post-void bladder scan shows 40 mL residual volume. What is the most appropriate next step in her management?
Renal & Urology UK Medical PG Practice Questions and MCQs
Question 11: A 42-year-old woman presents with a 2-day history of dysuria, urinary frequency, and visible haematuria. She reports similar episodes twice in the past year. She has no fever or loin pain. Urine dipstick shows blood 3+, leucocytes 2+, nitrites positive, protein 1+. Midstream urine culture grows >10^5 colony-forming units/mL of Escherichia coli sensitive to trimethoprim and nitrofurantoin. What is the most appropriate next step in her management after completing antibiotic treatment?
A. Arrange cystoscopy and renal tract ultrasound to investigate for underlying pathology (Correct Answer)
B. Prescribe prophylactic low-dose nitrofurantoin for 6 months
C. Provide patient with standby antibiotics for future episodes
D. Repeat urine culture after treatment to ensure eradication
E. Reassure and discharge with advice on fluid intake and post-coital voiding
Explanation: ***Arrange cystoscopy and renal tract ultrasound to investigate for underlying pathology***
- In a woman aged >40 years, the presence of **visible haematuria** (even during a UTI) necessitates investigation to rule out **urological malignancy** or structural abnormalities.
- While **recurrent UTIs** are common, the red-flag symptom of gross haematuria in this age group mandates **cystoscopy** and upper tract imaging per clinical guidelines.
*Prescribe prophylactic low-dose nitrofurantoin for 6 months*
- **Antibiotic prophylaxis** is a management strategy for recurrent UTIs, but it should only be considered after **underlying pathology** has been excluded via imaging.
- Starting prophylaxis prematurely could mask symptoms of a more serious condition like **bladder cancer** or **nephrolithiasis**.
*Provide patient with standby antibiotics for future episodes*
- **Self-start/Standby antibiotics** are useful for patients with frequent recurrences who can accurately self-diagnose, but this does not address the need for **haematuria investigation**.
- This approach is appropriate for symptomatic relief in verified low-risk patients, not as a primary step for a patient needing **red-flag investigations**.
*Repeat urine culture after treatment to ensure eradication*
- A **test of cure** is not routinely recommended for uncomplicated cystitis if the patient's symptoms have fully resolved.
- Focusing on **culture eradication** ignores the more critical clinical requirement to investigate the cause of **visible haematuria** in a 42-year-old.
*Reassure and discharge with advice on fluid intake and post-coital voiding*
- While **lifestyle modifications** such as hydration and post-coital voiding are helpful for prevention, they are insufficient for a patient with **visible haematuria**.
- Discharging the patient without further investigation would be unsafe, as it risks missing a diagnosis of **malignancy** or chronic renal calculi.
Question 12: A 75-year-old man with benign prostatic hyperplasia presents to the emergency department with a 12-hour history of complete inability to pass urine and severe suprapubic pain. Clinical examination reveals a palpable bladder extending to the umbilicus. A urinary catheter is successfully inserted, draining 1200 mL of urine immediately. Over the next 4 hours, he produces a further 2500 mL of urine. Blood tests show: sodium 145 mmol/L, potassium 3.8 mmol/L, creatinine 156 μmol/L (baseline 95 μmol/L). What is the most appropriate immediate management?
A. IV fluid replacement with 0.9% saline at 250 mL/hour
B. Restrict fluids to 1000 mL per 24 hours to prevent fluid overload
C. IV fluid replacement matching urine output plus insensible losses (Correct Answer)
D. Start furosemide 40 mg intravenously to manage polyuria
E. Emergency nephrology referral for urgent haemodialysis
Explanation: ***IV fluid replacement matching urine output plus insensible losses*** - This patient is experiencing **post-obstructive diuresis**, characterized by massive urine output (>200 mL/hr) following the relief of a severe urinary tract obstruction. - Management requires **replacement of fluid losses** (typically half-volume to full-volume matching) to prevent severe **hypovolemia**, hypotension, and potentially fatal electrolyte imbalances during the polyuric phase. *IV fluid replacement with 0.9% saline at 250 mL/hour* - A fixed rate of 250 mL/hour is insufficient for this patient, who has already produced **more than 600 mL/hour** in the last four hours. - Standard fixed rates may lead to a **net fluid deficit** and worsening of the patient's pre-existing **acute kidney injury** (evidenced by the elevated creatinine). *Restrict fluids to 1000 mL per 24 hours to prevent fluid overload* - Fluid restriction is dangerous in this context as the diuresis is a physiological response to **osmotic load** (retained urea/electrolytes) and impaired tubular concentration. - Restricting intake would rapidly lead to **dehydration**, severe **hypernatremia**, and potentially cardiovascular collapse. *Start furosemide 40 mg intravenously to manage polyuria* - Furosemide is a **loop diuretic** that would exacerbate renal losses and worsen the patient's fluid status rather than managing the polyuria. - Diuretics are **contraindicated** here as the polyuria is a result of post-obstructive recovery and not due to primary fluid overload. *Emergency nephrology referral for urgent haemodialysis* - There are no indications for **urgent hemodialysis**, such as refractory hyperkalemia, severe metabolic acidosis, or uremic complications. - The rise in creatinine is likely **pre-renal or post-renal** in nature and should improve with the relief of obstruction and appropriate volume replacement.
Question 13: A 58-year-old woman with rheumatoid arthritis treated with methotrexate and NSAIDs presents with a 3-day history of vomiting and diarrhoea. Her baseline creatinine is 78 μmol/L. Current blood tests show: creatinine 245 μmol/L, urea 18.2 mmol/L, sodium 132 mmol/L, potassium 5.2 mmol/L. Urinalysis shows no protein or blood. Renal ultrasound shows normal-sized kidneys with no hydronephrosis. What is the most likely underlying mechanism of her acute kidney injury?
A. Pre-renal acute kidney injury due to volume depletion (Correct Answer)
B. Acute tubular necrosis secondary to methotrexate toxicity
C. Acute interstitial nephritis from NSAID therapy
D. Obstructive uropathy from methotrexate crystalluria
E. Glomerulonephritis related to rheumatoid arthritis
Explanation: ***Pre-renal acute kidney injury due to volume depletion***
- The patient's 3-day history of **vomiting and diarrhoea** indicates significant **volume depletion**, leading to decreased renal perfusion. This is supported by the marked increase in **creatinine (78 to 245 μmol/L)** and the high **urea-to-creatinine ratio**.
- Her use of **NSAIDs** exacerbates pre-renal AKI by inhibiting **prostaglandin synthesis**, which normally causes **afferent arteriolar vasodilation** to maintain renal blood flow, especially in hypovolemic states.
*Acute tubular necrosis secondary to methotrexate toxicity*
- While methotrexate can cause renal injury, it is typically associated with **high doses** used in oncology, not the lower doses prescribed for **rheumatoid arthritis**.
- **Acute tubular necrosis (ATN)** would usually present with **granular casts** or renal tubular epithelial cells on urinalysis, which are not mentioned in this case.
*Acute interstitial nephritis from NSAID therapy*
- **Acute interstitial nephritis (AIN)** often presents with **eosinophilia**, **pyuria**, or significant **proteinuria**, none of which are reported in the urinalysis.
- AIN is an idiosyncratic hypersensitivity reaction, which is less likely given the acute onset following a clear episode of **gastrointestinal fluid loss**.
*Obstructive uropathy from methotrexate crystalluria*
- The **renal ultrasound** specifically showed **normal-sized kidneys with no hydronephrosis**, effectively ruling out any form of **obstructive uropathy**.
- Methotrexate **crystalluria** is also primarily a concern with very high doses and would typically lead to obstruction and associated imaging findings.
*Glomerulonephritis related to rheumatoid arthritis*
- This diagnosis is highly unlikely because **glomerulonephritis** typically involves **haematuria** and/or **significant proteinuria** on urinalysis, both of which are absent.
- The acute presentation following an episode of **vomiting and diarrhoea** is inconsistent with the more chronic or subacute progression of **rheumatoid arthritis-related glomerulonephritis**.
Question 14: A 62-year-old man with chronic kidney disease stage 3b (eGFR 40 mL/min/1.73m²) is being evaluated for worsening renal function. His medication history includes ramipril, atorvastatin, and amlodipine. Blood tests show: haemoglobin 102 g/L, ferritin 450 μg/L, transferrin saturation 18%, serum vitamin B12 320 ng/L, folate 8 μg/L. What is the most appropriate interpretation of these haematological findings?
A. Anaemia of chronic kidney disease with functional iron deficiency (Correct Answer)
B. Iron deficiency anaemia due to gastrointestinal blood loss
C. Combined vitamin B12 and folate deficiency
D. Anaemia secondary to ACE inhibitor therapy
E. Normal variant requiring no intervention
Explanation: ***Anaemia of chronic kidney disease with functional iron deficiency***
- The patient's **haemoglobin of 102 g/L** indicates anaemia, which is common in **CKD stage 3b (eGFR 40 mL/min/1.73m²)** due to reduced **erythropoietin** production by the kidneys.
- The **ferritin of 450 μg/L** suggests adequate iron stores, but a **transferrin saturation (TSAT) of 18%** (below the target of >20% in CKD patients) indicates **functional iron deficiency**, where iron is sequestered and not available for erythropoiesis due to inflammation.
*Iron deficiency anaemia due to gastrointestinal blood loss*
- **Absolute iron deficiency anaemia**, often caused by chronic blood loss (e.g., GI bleeding), is typically characterized by **low ferritin levels** (usually <100 μg/L in CKD patients).
- This patient's **ferritin of 450 μg/L** makes absolute iron deficiency unlikely; instead, it points towards sufficient iron stores but impaired utilization due to chronic inflammation.
*Combined vitamin B12 and folate deficiency*
- The patient's **serum vitamin B12 (320 ng/L)** and **folate (8 μg/L)** levels are within normal limits, ruling out deficiencies in these vitamins as the primary cause of anaemia.
- Deficiencies in these vitamins typically lead to **macrocytic anaemia**, whereas anaemia of CKD is usually **normocytic**.
*Anaemia secondary to ACE inhibitor therapy*
- While **ramipril (an ACE inhibitor)** can occasionally cause a mild reduction in haemoglobin by decreasing erythropoietin production, it is rarely the sole cause of significant anaemia, especially with the observed iron profile.
- The combination of **low TSAT** and **high ferritin** strongly suggests functional iron deficiency and anaemia of CKD as the predominant factors, rather than a drug-induced anaemia alone.
*Normal variant requiring no intervention*
- A **haemoglobin level of 102 g/L** is significantly below the normal range for adult males, indicating true **anaemia** that requires medical attention and intervention, particularly in the context of advanced CKD.
- Anaemia in CKD is a serious condition that contributes to patient morbidity and mortality and necessitates management, typically with iron supplementation and potentially erythropoiesis-stimulating agents.
Question 15: A 45-year-old woman presents to the emergency department with severe muscle weakness and palpitations. She has a history of hypertension treated with lisinopril and bendroflumethiazide. ECG shows tall tented T waves and a prolonged PR interval. Blood tests reveal: sodium 138 mmol/L, potassium 7.8 mmol/L, creatinine 95 μmol/L, glucose 5.2 mmol/L. Which medication should be given first to protect against the cardiac effects of hyperkalaemia?
A. 10 units of insulin with 50 mL of 50% glucose intravenously
B. 10 mL of 10% calcium gluconate intravenously (Correct Answer)
C. 15 mg salbutamol nebuliser
D. Sodium polystyrene sulfonate 15 g orally
E. Sodium bicarbonate 50 mmol intravenously
Explanation: ***10 mL of 10% calcium gluconate intravenously***
- This is the **priority intervention** for severe hyperkalaemia with ECG changes (tall tented T waves, prolonged PR interval) because it **stabilizes the myocardial membrane** and reduces the risk of lethal arrhythmias.
- It works within **1-3 minutes** by antagonizing the cardiac effects of potassium, effectively "buying time" for more definitive potassium-lowering therapies, though it does not lower the serum potassium level itself.
*10 units of insulin with 50 mL of 50% glucose intravenously*
- This treatment helps **lower serum potassium** by shifting it into the **intracellular compartment**, but its onset of action is typically slower (15-30 minutes) than calcium gluconate for cardiac protection.
- It should be administered as a second step after the heart has been protected with **intravenous calcium** due to its delayed onset for urgent cardioprotection.
*15 mg salbutamol nebuliser*
- **Beta-2 agonists** like salbutamol stimulate the Na+/K+ ATPase pump to drive potassium into cells, but their onset of action is slower (30-90 minutes) compared to calcium or insulin.
- It is used as an **adjunctive therapy** to lower potassium and is not the first-line agent for immediate cardiac membrane stabilization in severe hyperkalaemia.
*Sodium polystyrene sulfonate 15 g orally*
- This is a **cation-exchange resin** that removes potassium from the body via the gastrointestinal tract, but it has a **delayed onset** of several hours.
- It is **not suitable for emergency management** of acute, severe hyperkalaemia with ECG changes, as it cannot provide rapid cardioprotection.
*Sodium bicarbonate 50 mmol intravenously*
- Sodium bicarbonate can shift potassium intracellularly by increasing blood pH, but it is generally reserved for patients with concurrent **metabolic acidosis** and is less effective than calcium for immediate cardiac stabilization.
- In this clinical scenario, it is **less potent** and has a slower onset for urgent cardioprotection compared to calcium gluconate.
Question 16: A 47-year-old woman presents with severe nausea and decreased urine output 24 hours after undergoing contrast-enhanced CT pulmonary angiogram for suspected pulmonary embolism. Her background includes type 2 diabetes (HbA1c 76 mmol/mol) and hypertension treated with lisinopril and metformin. Pre-CT creatinine was 142 μmol/L. Current blood tests show: creatinine 287 μmol/L, urea 19.4 mmol/L, potassium 5.2 mmol/L. Urinalysis shows muddy brown casts. Which feature of her presentation would most strongly indicate a need for urgent haemodialysis?
A. Creatinine rise of >100% within 24 hours suggesting severe acute kidney injury
B. Development of pulmonary oedema with oxygen saturation 88% on air despite diuretics (Correct Answer)
C. Persistent metabolic acidosis with pH 7.28 and bicarbonate 16 mmol/L
D. Serum potassium of 5.2 mmol/L with ECG changes of peaked T waves
E. Urea level of 19.4 mmol/L indicating uraemic symptoms
Explanation: ***Development of pulmonary oedema with oxygen saturation 88% on air despite diuretics***- This represents **refractory fluid overload**, a critical component of the **AEIOU mnemonic** for urgent haemodialysis indications.- In the context of **acute kidney injury (AKI)**, hypoxia failing to respond to medical management is a life-threatening emergency requiring immediate renal replacement therapy.*Creatinine rise of >100% within 24 hours suggesting severe acute kidney injury*- While this indicates **AKI Stage 3**, the absolute level or rate of creatinine rise itself is not an independent indication for dialysis without associated clinical complications.- Initial management focuses on **fluid balance**, treating the underlying cause, and monitoring for physiological instability rather than immediate dialysis based solely on creatinine trends.*Persistent metabolic acidosis with pH 7.28 and bicarbonate 16 mmol/L*- Urgent dialysis for **acidosis** is generally reserved for a **pH < 7.20** or cases where medical therapy with bicarbonate is ineffective or contraindicated.- A pH of 7.28 with a bicarbonate of 16 mmol/L indicates a moderate acidosis, which should initially be managed medically and typically does not meet the threshold for **emergent intervention** with dialysis.*Serum potassium of 5.2 mmol/L with ECG changes of peaked T waves*- **Hyperkalaemia** typically mandates urgent dialysis only when levels exceed **6.5 mmol/L** or when severe ECG changes (e.g., wide QRS, ventricular arrhythmias) persist despite medical management (e.g., calcium gluconate, insulin-glucose).- A potassium of 5.2 mmol/L is mildly elevated, and **peaked T waves** at this level would still warrant medical management rather than immediate dialysis.*Urea level of 19.4 mmol/L indicating uraemic symptoms*- **Uraemia** is an indication for dialysis only when it leads to severe clinical complications such as **pericarditis**, **encephalopathy**, overt **uraemic bleeding**, or profound neurological changes.- A urea level of 19.4 mmol/L is elevated but does not automatically mandate dialysis unless these severe **clinical manifestations** are present.
Question 17: A 61-year-old man with CKD stage 5 (eGFR 12 mL/min/1.73m²) presents for pre-dialysis assessment. His blood tests show: haemoglobin 92 g/L, ferritin 380 ng/mL, transferrin saturation 28%, PTH 68 pmol/L (reference 1.6-6.9 pmol/L), corrected calcium 2.28 mmol/L, phosphate 1.89 mmol/L, 25-OH vitamin D 32 nmol/L, bicarbonate 18 mmol/L. Which intervention would address the greatest number of complications in this patient?
A. Commence erythropoietin stimulating agent for anaemia of CKD
B. Start oral alfacalcidol to manage secondary hyperparathyroidism
C. Prescribe oral sodium bicarbonate to correct metabolic acidosis (Correct Answer)
D. Initiate sevelamer as phosphate binder to prevent hyperphosphataemia
E. Arrange renal transplant assessment as definitive treatment
Explanation: ***Prescribe oral sodium bicarbonate to correct metabolic acidosis***- Correcting **metabolic acidosis** (bicarbonate 18 mmol/L) in CKD stage 5 is crucial as it **slows CKD progression**, improves **nutritional status** by reducing protein catabolism, and mitigates **muscle wasting**.- It also benefits **renal bone disease** by decreasing acid buffering from bone, and can enhance the effectiveness of **erythropoietin-stimulating agents** for anaemia.*Commence erythropoietin stimulating agent for anaemia of CKD*- While the patient has **anaemia (Hb 92 g/L)**, commencing an ESA primarily targets only this specific complication.- It does not address the **metabolic acidosis**, **hyperphosphataemia**, or **secondary hyperparathyroidism**, which contribute to broader systemic issues.*Start oral alfacalcidol to manage secondary hyperparathyroidism*- This addresses the **elevated PTH (68 pmol/L)**, but the patient also has **nutritional vitamin D deficiency (25-OH vitamin D 32 nmol/L)**, which should ideally be corrected first or concurrently.- It specifically targets mineral bone disease and doesn't comprehensively address other significant issues like **metabolic acidosis** or **anaemia**.*Initiate sevelamer as phosphate binder to prevent hyperphosphataemia*- While the patient has **hyperphosphataemia (phosphate 1.89 mmol/L)**, this intervention solely focuses on phosphate binding.- It does not provide the broad benefits for **CKD progression**, **nutritional status**, or **acid-base balance** that correcting metabolic acidosis offers.*Arrange renal transplant assessment as definitive treatment*- **Renal transplantation** is the definitive long-term treatment for ESRD, but it is not an immediate intervention to address the current array of biochemical derangements.- Prior to transplantation, patients require **medical stabilization** and optimization of their complications, such as **metabolic acidosis**, to improve surgical outcomes and readiness.
Question 18: A 35-year-old man presents to the emergency department with a 4-hour history of severe right loin pain, haematuria, and vomiting. CT KUB confirms a 4mm stone in the right ureter with mild hydronephrosis. He is treated with IM diclofenac and IV fluids. Six hours later, he develops fever of 38.7°C with rigors. Blood tests show: WBC 17.8 × 10⁹/L, CRP 142 mg/L, creatinine 156 μmol/L (baseline 88 μmol/L). Blood pressure is 98/62 mmHg, pulse 118 bpm. What is the most appropriate immediate management?
A. Start IV broad-spectrum antibiotics and arrange emergency ureteroscopy within 6 hours
B. Start IV antibiotics and arrange urgent percutaneous nephrostomy or retrograde ureteric stenting (Correct Answer)
C. Administer further IV fluids and continue conservative management with oral antibiotics
D. Arrange urgent extracorporeal shock wave lithotripsy under antibiotic cover
E. Start IV antibiotics and arrange elective stone removal after infection resolution in 2-4 weeks
Explanation: ***Start IV antibiotics and arrange urgent percutaneous nephrostomy or retrograde ureteric stenting***
- The patient presents with **obstructive pyelonephritis** (infected hydronephrosis) and clear signs of **urosepsis** (fever, rigors, leukocytosis, AKI, hypotension, tachycardia) in the presence of an obstructing ureteric stone.
- **Immediate decompression** of the collecting system via a **percutaneous nephrostomy** or **retrograde ureteric stent** is crucial to drain infected urine and relieve the obstruction, preventing septic shock and further kidney damage; this must be initiated alongside **broad-spectrum IV antibiotics**.
*Start IV broad-spectrum antibiotics and arrange emergency ureteroscopy within 6 hours*
- While IV antibiotics are essential, **emergency ureteroscopy** is generally contraindicated in active infection and sepsis because the high-pressure irrigation used during the procedure can worsen bacteremia and lead to **septic shock**.
- The priority in this critical scenario is urgent **drainage and source control**, which ureteroscopy for stone removal does not safely achieve in the acute septic phase; definitive stone management is typically deferred until the infection is under control.
*Administer further IV fluids and continue conservative management with oral antibiotics*
- The patient is in a state of **sepsis** with signs of **acute kidney injury** due to an obstructed, infected kidney, which constitutes a medical emergency requiring prompt and active intervention, not conservative management.
- **Oral antibiotics** are entirely insufficient for systemic urosepsis, and mere fluid resuscitation without addressing the physical **obstruction** will not resolve the infection or prevent severe clinical deterioration.
*Arrange urgent extracorporeal shock wave lithotripsy under antibiotic cover*
- **ESWL** is primarily designed for stone fragmentation and does not provide the immediate drainage of infected urine from an obstructed system, which is the most critical intervention for managing **urosepsis**.
- Performing ESWL on an acutely infected and obstructed kidney can exacerbate the patient's **sepsis** by potentially forcing bacteria into the bloodstream and does not offer the necessary prompt relief of obstruction and drainage.
*Start IV antibiotics and arrange elective stone removal after infection resolution in 2-4 weeks*
- Delaying definitive decompression for **2-4 weeks** in a septic patient with an obstructed kidney is life-threatening, as it significantly increases the risk of irreversible septic shock, multi-organ failure, and mortality.
- Although IV antibiotics are crucial, the **urgent need for drainage** to relieve the obstruction and eliminate the primary source of infection cannot be postponed in the presence of systemic inflammatory response.
Question 19: A 41-year-old man with autosomal dominant polycystic kidney disease and CKD stage 3a (eGFR 52 mL/min/1.73m²) is commenced on tolvaptan following nephrologist review. He is counselled about potential adverse effects. Which of the following monitoring protocols is most critical for this medication?
A. Monthly full blood count monitoring for bone marrow suppression
B. Weekly serum potassium for risk of hyperkalaemia
C. Monthly urine protein quantification for progression of proteinuria
D. Baseline and regular monthly liver function tests for hepatotoxicity (Correct Answer)
E. Three-monthly echocardiography for valvular heart disease
Explanation: ***Baseline and regular monthly liver function tests for hepatotoxicity***- **Tolvaptan** is associated with a risk of idiosyncratic **drug-induced liver injury (DILI)**, which can be severe or even life-threatening.- Regulatory guidelines mandate **liver function test (LFT)** monitoring at baseline, monthly for the first 18 months, and every 3 months thereafter.*Monthly full blood count monitoring for bone marrow suppression*- **Tolvaptan** is a selective **vasopressin V2 receptor antagonist** and does not have known associations with **myelosuppression**.- Routine **full blood count (FBC)** monitoring is not indicated for patients on this specific therapy.*Weekly serum potassium for risk of hyperkalaemia*- Unlike ACE inhibitors or ARBs, tolvaptan does not typically cause **hyperkalaemia**; its primary electrolyte concern is **hypernatraemia** due to free water clearance.- While monitoring electrolytes is part of general CKD care, weekly **potassium** monitoring is not a specific requirement for tolvaptan safety protocols.*Monthly urine protein quantification for progression of proteinuria*- Tolvaptan is used to slow the increase in **kidney volume** and the decline in **eGFR** in ADPKD, not specifically to manage **proteinuria**.- **Urine protein quantification** is not the primary safety monitoring parameter required for this medication.*Three-monthly echocardiography for valvular heart disease*- There is no clinical evidence linking tolvaptan to the development of **valvular heart disease**.- Regular **echocardiography** is not part of the standard monitoring protocol for patients initiated on **V2 receptor antagonists**.
Question 20: A 67-year-old woman is being investigated for recurrent urinary tract infections. She has had 5 documented UTIs in the past 8 months, each confirmed with positive urine culture and responding to antibiotics. She is postmenopausal and has type 2 diabetes (HbA1c 58 mmol/mol). Renal ultrasound shows normal kidneys with no evidence of obstruction or stones. Post-void bladder scan shows 40 mL residual volume. What is the most appropriate next step in her management?
A. Arrange cystoscopy to exclude bladder pathology
B. Prescribe vaginal oestrogen therapy and review in 3 months (Correct Answer)
C. Commence intermittent self-catheterization to reduce residual volumes
D. Refer to gynaecology for pelvic floor repair surgery
E. Start continuous antibiotic prophylaxis with trimethoprim for 6 months
Explanation: ***Prescribe vaginal oestrogen therapy and review in 3 months***- In **postmenopausal women**, **estrogen deficiency** causes **urogenital atrophy**, leading to changes in vaginal pH and flora (loss of protective lactobacilli), which significantly increases susceptibility to **recurrent UTIs**.- **Topical vaginal estrogen** is the **first-line non-antibiotic treatment** for preventing recurrent UTIs in this population, as it restores the vaginal and urethral mucosa and re-establishes a healthy urogenital microbiome.*Arrange cystoscopy to exclude bladder pathology*- **Cystoscopy** is typically reserved for cases with **haematuria**, suspected bladder cancer, stones, or persistent symptoms despite initial management, none of which are strongly indicated here.- The **renal ultrasound** was normal, and the UTIs respond to antibiotics, suggesting no obvious structural pathology requiring immediate invasive investigation.*Commence intermittent self-catheterization to reduce residual volumes*- A **post-void residual (PVR)** of 40 mL is considered **normal** (typically <50-100 mL), indicating adequate bladder emptying.- **Intermittent self-catheterization** is an invasive procedure indicated for significant urinary retention (PVR >150-200 mL) and would introduce unnecessary risks of infection and discomfort in this patient.*Refer to gynaecology for pelvic floor repair surgery*- There are no signs or symptoms mentioned (e.g., vaginal bulge, pressure, incontinence strongly linked to prolapse) to suggest a significant **pelvic organ prolapse** requiring surgical intervention.- **Pelvic floor repair surgery** is a major intervention and would not be the initial step for recurrent UTIs without clear evidence of severe prolapse contributing significantly to the problem.*Start continuous antibiotic prophylaxis with trimethoprim for 6 months*- **Continuous antibiotic prophylaxis** should generally be considered *after* non-antibiotic measures, such as **vaginal estrogen therapy**, have been tried and failed or are contraindicated.- Immediate long-term antibiotic use increases the risk of **antibiotic resistance** and side effects, making it a second-line approach when an underlying modifiable factor like estrogen deficiency is present.
